Postępy Dermatologii i Alergologii

Full text

4/2026 vol. 43
Original paper

Exploration of a simple indicator prediction model for omalizumab efficacy in chronic inducible urticaria

Lu Wang 1
,
Xiaoping Zhang 1
,
Fumin Fang 1

  1. Department of Dermatology and Venereology, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, China

Adv Dermatol Allergol 2026; XLIII (4): 441-449

DOI: https://doi.org/10.5114/ada.2026.164328
Data publikacji online: 2026/09/14
Article file
PDiA Exploration.pdf
  1. Pozderac I, Lugoviæ-Mihiæ L, Artukoviæ M, et al. Chronic inducible urticaria: classification and prominent features of physical and non-physical types. Acta Dermatovenerol Alp Pannonica Adriat 2020; 29: 141-8.
  2. Ritzel D, Altrichter S. Chronic Inducible Urticaria. Immunol Allergy Clin N Am 2024; 44: 439-52.
  3. Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. J Allergy Clin Immunol 2017; 141: 638-49.
  4. Yu M, Terhorst-Molawi D, Altrichter S, et al. Omalizumab in chronic inducible urticaria: A real-life study of efficacy, safety, predictors of treatment outcome and time to response. Clin Exp Allergy 2021; 51: 730-4.
  5. Expósito-Serrano V, Curto-Barredo L, Aguilera Peiro P, et al. Omalizumab for the treatment of chronic inducible urticaria in 80 patients. Br J Dermatol 2021; 184: 167-8.
  6. Ornek Ozdemir S, Can PK, Degirmentepe EN, et al. Unveiling treatment response predictors in predominant subtypes of chronic inducible urticaria. Int Arch Allergy Immunol 2024; 185: 1055-65.
  7. Soegiharto R, Alizadeh Aghdam M, Sørensen JA, et al. Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation. JAMA Dermatol 2024; 160: 927-35.
  8. Ertaş R, Özyurt K, Atasoy M, et al. The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. Allergy 2018; 73: 705-12.
  9. Chuang KW, Hsu CY, Huang SW, Chang HC. Association between serum total IgE levels and clinical response to omalizumab for chronic spontaneous urticaria: a systematic review and meta-analysis. J Clin Immunol Practice 2023; 11: 2382-9.e3.
  10. Fabi A, Milosavljevic S, Lang CCV, et al. Predictive value of the systemic immune inflammation index and systemic inflammatory response index on omalizumab drug survival in chronic spontaneous urticaria. Allergo J Int 2024; 33: 32-40.
  11. Önder S, Ozturk M. How does omalizumab affect the immunoinflammatory response in patients with chronic spontaneous urticaria? Cutan Ocular Toxicol 2020; 39: 31-5.
  12. Ritzel D, Altrichter S. Chronic inducible urticaria. Immunol Allergy Clin N Am 2024; 44: 439-52.
  13. Giménez-Arnau A, Salman A, Podder I. Biomarkers to predict therapeutic response in chronic spontaneous urticaria: a review. Eur J Dermatol 2024; 34: 3-12.
  14. Kolkhir P, Muñoz M, Asero R, et al. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol 2022; 149: 1819-31.
  15. Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias – The EAACI/GA(2)LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy 2016; 71: 780-802.
  16. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022; 77: 734-66.
  17. Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004; 113: 297-302.
  18. Chuang KW, Hsu CY, Huang SW, Chang HC. Association between serum total IgE levels and clinical response to omalizumab for chronic spontaneous urticaria: a systematic review and meta-analysis. J Allergy Clin Immunol In Practice 2023; 11: 2382-9.e3.
  19. Lee HY, Jeon HS, Jang JH, et al. Predicting responses to omalizumab in antihistamine-refractory chronic urticaria: a real-world longitudinal study. J Allergy Clin Immunol 2024; 3: 100245.
  20. Ensina LF, Brandão L, Arruda LK, et al. IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria. Front Allergy 2025; 5: 1451296.
  21. Kolkhir P, Muñoz M, Asero R, et al. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol 2022; 149: 1819-31.
  22. Brás R, Esteves Caldeira L, Bernardino A, Costa C. Anti-TPO IgG/total IgE ratio: biomarker for omalizumab response prediction in chronic spontaneous urticaria. Int Arch Allergy Immunol 2023; 184: 866-9.
  23. Kolkhir P, Altrichter S, Hawro T, Maurer M. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria. Allergy 2018; 73: 940-8.
  24. Branicka O, Rymarczyk B, Gawlik R, Glück J. Assessment of ELR, PLR, NLR and BLR ratios during omalizumab treatment of chronic spontaneous urticaria. J Clin Med 2024; 13: 4287.
  25. Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol 2014; 133: 1365-72.e13726.
  26. Buttgereit T, Salameh P, Sydorenko O, et al. The 7-day recall period version of the Urticaria Control Test-UCT-7. J Allergy Clin Immunol 2023; 152: 1210-7.e14.
  27. Moñino-Romero S, Kolkhir P, Ohanyan T, et al. Elevated baseline soluble FceRI may be linked to early response to omalizumab treatment in chronic spontaneous urticaria. J Eur Acad Dermatol Venereol 2024; 38: 167-74.
  28. Magerl M, Abajian M, Krause K, et al. An improved Peltier effect-based instrument for critical temperature threshold measurement in cold- and heat-induced urticaria. J Eur Acad Dermatol Venereol 2015; 29: 2043-5.
  29. Schoepke N, Abajian M, Church MK, Magerl M. Validation of a simplified provocation instrument for diagnosis and threshold testing of symptomatic dermographism. Clin Exp Dermatol 2015; 40: 399-403.
  30. Gaebelein-Wissing N, Ellenbogen E, Lehmann P. Solar urticaria: Clinic, diagnostic, course and therapy management in 27 patients. JDDG 2020; 18: 1261-8.
  31. Altrichter S, Salow J, Ardelean E, et al. Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria. J Dermatol Sci 2014; 75: 88-93.
  32. Maurer M, Schütz A, Weller K, et al. Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial. J Allergy Clin Immunol 2017; 140: 870-3.e5.
  33. Metz M, Schütz A, Weller K, et al. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial. J Allergy Clin Immunol 2017; 140: 864-7.e5.
  34. Soegiharto R, Alizadeh Aghdam M, Sørensen JA, et al. Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study. Allergy 2025; 80: 489-99.
  35. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decision Making 2006; 26: 565-74.
  36. Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to interpreting decision curve analysis. Diagn Progn Res 2019; 3: 18.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Indexed in
pubmed
Integrated with
integrated with publons
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications